News | April 25, 2026
Bayer’s comeback gains speed as CEO warns: “The Work Isn’t Complete. Yet"
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
The collaboration will roll out an “agentic” AI platform across Merck’s research & development, manufacturing, commercial, and corporate operations
Growth was broad-based across segments
Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing
The investment will bring in cutting-edge downstream fermentation technology, strengthening the company’s contract manufacturing capabilities for drug substances
With a PhD in Biochemistry and an executive MBA, she brings nearly two decades of experience in the in vitro diagnostics (IVD) sector
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
Subscribe To Our Newsletter & Stay Updated
